We study targeted therapy in combination with immunotherapy for cancer treatment, using graphene oxide-formulated anticancer antibodies along with tumor-targeted delivery of immune cytokines. Our goal is to convert tumor necroptosis into tumor vaccine in situ to overcome intratumor tolerogenic microenvironment. We also investigate mechanisms of cancer cell necroptosis brought about by graphene oxide-formulation anticancer antibodies.
3i Bridge/Pillar: Cancer
Keywords: anticancer antibodies, graphene oxide, necroptosis